Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 2929-year-old woman is evaluated in the neurology clinic to discuss disease-modifying therapy for her relapsing-remitting multiple sclerosis. She was diagnosed 22 years ago and has experienced 33 clinical relapses over the past year despite consistent compliance with glatiramer acetate therapy. Magnetic resonance imaging of the brain and cervical spine reveals multiple new gadolinium-enhancing lesions. After a thorough discussion of risks and benefits, the decision is made to transition her to oral fingolimod.

Based on the specific mechanism of action and adverse effect profile of fingolimod, which of the following baseline and ongoing monitoring protocols are strictly required for this patient? (Select 22 answers)

  1. Continuous electrocardiographic monitoring for 66 hours following the first doseCevap
  2. Baseline and periodic dilated ophthalmologic examinationsCevap
  3. C
    Serial serum anti-JC virus antibody index testing
  4. D
    Routine assessment of left ventricular ejection fraction via echocardiography
  5. E
    Monthly testing of serum thyroid-stimulating hormone levels

Cevap

Continuous electrocardiographic monitoring for 66 hours following the first dose AND Baseline and periodic dilated ophthalmologic examinations
Fingolimod acts as a sphingosine-1-phosphate (S1P) receptor modulator. Because S1P receptors are present in both lymph nodes and atrial myocytes, initial binding causes a transient decrease in heart rate and potential atrioventricular conduction delays. Thus, continuous electrocardiographic monitoring for 66 hours post-dose is required. Furthermore, the drug alters vascular permeability, leading to a well-documented risk of fingolimod-associated macular edema (FAME). This strictly mandates a baseline dilated ophthalmologic evaluation and follow-up at 33 to 44 months.

Adım Adım Çözüm

1
Identify the specific pharmacological agent and its drug class.
The prescribed drug is fingolimod, which acts as a sphingosine-1-phosphate (S1P) receptor modulator.
Different multiple sclerosis therapies have entirely distinct mechanisms of action that dictate their unique safety and monitoring protocols.
2
Recall the mechanism-specific adverse effects associated with fingolimod.
Fingolimod causes early bradycardia/conduction blocks (due to S1P receptors in the heart) and increases vascular permeability leading to macular edema.
Regulatory guidelines and standard of care require monitoring to prevent severe outcomes from these specific anticipated side effects.
3
Match the required surveillance protocols to the identified adverse effects.
The cardiac risk necessitates 66-hour continuous electrocardiography upon initiation, and the macular risk necessitates baseline and periodic dilated ophthalmologic examinations.
These protocols directly mitigate the morbidity of first-dose bradycardia and fingolimod-associated macular edema (FAME).
4
Rule out monitoring parameters associated with other disease-modifying therapies.
JC virus testing, echocardiography, and monthly TSH are excluded as they are indicated for natalizumab, mitoxantrone, and alemtuzumab, respectively.
Applying the wrong screening protocol exposes the patient to unnecessary testing while missing critical drug-specific toxicities.

Anahtar Kavram

Patients initiated on fingolimod for multiple sclerosis require first-dose continuous electrocardiography for 66 hours to monitor for bradyarrhythmias, and baseline/periodic ophthalmologic exams to monitor for macular edema.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru